 |
|
Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
December 10, 2008SAN FRANCISCO - More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.
Among patients 65 or younger, 52 percent survived without disease recurrence at a median of seven years of follow-up, said first author Jorge Romaguera, M.D., professor in M. D. Anderson's Department of Lymphoma and Myeloma. Overall survival for this subgroup was 68 percent.
"There is some disagreement about whether these younger patients should receive a bone marrow transplant as frontline therapy rather than chemotherapy," Romaguera said. "Our results with chemotherapy are as good as any transplant data. We don't believe a transplant is necessary as a first treatment in newly diagnosed mantle cell lymphoma."
Mantle cell lymphoma is one of the most lethal versions of non-Hodgkin lymphoma. Romaguera and colleagues have followed 97 patients for up to nine years who received rituximab plus a combination of chemotherapies known as hyperCVAD, alternated with rituximab plus high-dose methotrexate/cytarabine in 6-8 cycles.
Out of those patients, 87 percent achieved either a complete response or unconfirmed complete response after six cycles. Of 65 patients who were 65 or younger, 30 relapsed. Of 32 patients older than 65, a total of 23 relapsed.
Overall survival for the entire group, including all ages up to 80 years, was 60 percent; 43 percent were at failure-free survival, with no recurrence of the disease, at seven years of median follow-up.
Survival is about the same for patients who undergo stem cell transplantation, Romaguera said. No randomized studies between the chemotherapy regimen, stem cell transplants or the chemotherapy plus stem cell transplant have been done.
About 3,500 new cases of mantle cell lymphoma are diagnosed in the United States annually. The average age of diagnosis is the mid-sixties and median survival is about four years.
University of Texas M. D. Anderson Cancer Center
Mantle cell lymphoma is one of the most lethal versions of non-Hodgkin lymphoma. Romaguera and colleagues have followed 97 patients for up to nine years who received rituximab plus a combination of chemotherapies known as hyperCVAD, alternated with rituximab plus high-dose methotrexate/cytarabine in 6-8 cycles.
Out of those patients, 87 percent achieved either a complete response or unconfirmed complete response after six cycles. Of 65 patients who were 65 or younger, 30 relapsed. Of 32 patients older than 65, a total of 23 relapsed.
Overall survival for the entire group, including all ages up to 80 years, was 60 percent; 43 percent were at failure-free survival, with no recurrence of the disease, at seven years of median follow-up.
Survival is about the same for patients who undergo stem cell transplantation, Romaguera said. No randomized studies between the chemotherapy regimen, stem cell transplants or the chemotherapy plus stem cell transplant have been done.
About 3,500 new cases of mantle cell lymphoma are diagnosed in the United States annually. The average age of diagnosis is the mid-sixties and median survival is about four years.
University of Texas M. D. Anderson Cancer Center
Lymphoma Current Events and Lymphoma News RSSResearchers find new way to attack inflammation in Graves' eye disease
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab.
Approved lymphoma drug shows promise in early tests against bone cancer
A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer.
Immunotherapy demonstrates long-term success in treating lymphoma
Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).
Exercise is good medicine for lymphoma patients
A healthy dose of exercise is good medicine, even for lymphoma patients receiving chemotherapy, University of Alberta researchers have found.
Childhood cancer survivors experience suicidal thoughts decades after diagnosis
Adult survivors of childhood cancer have an increased risk for suicidal thoughts, even decades after their cancer treatments ended, according to a study led by Dana-Farber Cancer Institute scientists.
New therapy for vasculitis will help patients avoid infertility and cancer
Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy.
Studying cancer in pet dogs to find new treatments for human patients
A team of scientists at the National Cancer Institute (NCI) in Bethesda, USA, says that studying pet dogs with cancer could yield valuable information on how to diagnose and treat human cancers.
Scientists identify genetic cause of previously undefined primary immune deficiency disease
Researchers at the National Institutes of Health have identified a genetic mutation that accounts for a perplexing condition found in people with an inherited immunodeficiency.
Certain cancers more common among HIV patients than non-HIV patients
Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s.
Identification of highly radiosensitive patients may lead to side effect-free radiotherapy
An international group of scientists has taken the first step on the road to targeting radiotherapy dosage to individual patients by means of their genetic characteristics.
More Lymphoma Current Events and Lymphoma News Articles
 |
Living with Lymphoma: A Patient's Guide by Elizabeth M. Adler PhD (Author) "Adler's professional background and experience as a lymphoma survivor make her the perfect person to write this book. The author's explanations are a gentle guide and a thorough introduction to the basics that give us the confidence to handle decisions relating to treatments and other aspects of lymphoma." -- Anne Atkinson, non-Hodgkin lymphoma and Hodgkin disease survivor and coordinator of the Women's Cancer Group |
 |
100 Questions & Answers About Lymphoma by Peter Holman (Author), Jodi Garrett (Author), William D. Jansen (Author) This text is a patient-oriented guide to dealing with lymphoma. Questions and answers cover basic questions about the disease such as risk factors and causes; methods of prevention, screening, and diagnosis; available treatments and how to choose among them; and ways of coping with common emotional and physical difficulties associated with the diagnosis and treatment. Dr. Holman is a practicing oncologist, and Ms. Garrett is an oncology nurse; the pair team up to provide both a doctor’s and a caregiver’s perspective in answering these common questions. |
 |
Non-Hodgkin Lymphomas by James O Armitage (Editor), Peter M Mauch (Editor), Nancy Lee Harris (Editor), Bertrand Coiffier (Editor), Riccardo Dalla-Favera (Editor) Thoroughly updated for its Second Edition, Non-Hodgkin Lymphomas is the definitive textbook on the biology, diagnosis, staging, and treatment of all forms of non-Hodgkin lymphomas. With backgrounds in medical and radiation oncology, molecular biology, and pathology, the editors and contributors provide an international, multidisciplinary approach to the topic. This edition is the first text using the new World Health Organization classification of non-Hodgkin lymphomas. The book offers complete coverage of the most current techniques for diagnosis, staging, and treatment, the approach to specific types of lymphoma, and special problems common to the management of patients with these disorders. A companion Website includes the fully searchable text and downloadable images. |
 |
Lymphoma (Fast Facts) by Chris Hatton (Author), Graham Collins (Author), John, M.D. Sweetenham (Author) Lymphomas arise from a single abnormal lymphocyte, yet many different subtypes of lymphoma occur. Recent advances in cellular and molecular techniques have revolutionized physicians' understanding of this malignancy, and there have been dramatic developments in diagnosis and treatment. "Fast Facts: Lymphoma" gives a comprehensive and up-to-date perspective on this challenging disease written by three experts in the field. Starting with a clear outline of the nature of lymphoma, its diagnosis, staging and management, this concise handbook goes on to provide specific details of individual lymphoma entities and treatment modalities. "Fast Facts: Lymphoma" is a valuable handbook for training doctors and specialist nurses working in the field of hemato-oncology, and will be of interest to the... |
 |
Handcrafted Artisan Lymphoma Awareness Heart Pendant & Sterling Silver Chain Necklace 412 by Pendant@Joyful-Creations.com Pendant: Peridot Swarovski Austrian crystal bicones, sterling silver Bali bead cap & daisy spacers, sterling rounds. Crystal AB faceted Czech firepolished glass pear bead and sterling silver round dangle and pendant all handwrapped with sterling silver wire. Pendant drops approx. 2 1/2" and includes a sterling silver bale marked .925 on the back. Focal Bead: White polymer clay heart with beautiful lime green roses all around the heart, handmade by Uiko Ogawa. Show your support for a cure for Lymphoma, Non-Hodgkins Lymphoma, Lyme Disease, Muscular Dystrophy. 18" Sterling silver Italian Singapore chain included in this auction. Singapore chains are so elegant! They have a natural twist in their manufacture and therefore LOTS of sparkle. ** Gift Boxed - Ready for gift giving ** |
![Non Hogkins Lymphoma [Explicit]](http://ecx.images-amazon.com/images/I/51rD3aRGVML._SL160_.jpg) |
Non Hogkins Lymphoma [Explicit] Robert Schimmel (Primary Contributor) |
 |
New Design Green Lymphoma Awareness 8" Car Magnet by sci New Design Green Lymphoma Awareness 8" Car Magnet |
 |
Non-Hodgkin's Lymphoma Awareness Ribbon Mouse Pad by MyHeritageWear.com The Non-Hodgkin's Lymphoma Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Non-Hodgkin's Lymphoma Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Non-Hodgkin's Lymphoma Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Hodgkin Lymphoma by Richard T Hoppe (Editor), Peter M Mauch (Editor), James O Armitage (Editor), Volker Diehl (Editor), Lawrence M Weiss (Editor) The definitive text on Hodgkin lymphoma is now in its thoroughly revised, updated Second Edition. More than 100 recognized authorities from all parts of the world provide comprehensive, current information on every aspect of Hodgkin lymphoma, including etiology, epidemiology, biology, pathology, evaluation, staging, treatment, and follow-up. This edition describes the increased use of PET scanning in staging and follow-up. Chapters discuss current treatment options—including combination chemotherapy, radiation therapy, novel treatment techniques, and hematopoietic stem cell transplantation—and offer guidelines for treatment selection. Full consideration is given to late effects of therapy and clinical trials for assessing quality of life in patients. This edition includes... |
 |
Hodgkin Lymphoma Hardbound Textbook- Second Edition by lippincott and williams The definitive text on Hodgkin lymphoma is now in its thoroughly revised, updated Second Edition. More than 100 recognized authorities from all parts of the world provide comprehensive, current information on every aspect of Hodgkin lymphoma, including etiology, epidemiology, biology, pathology, evaluation, staging, treatment, and follow-up. This edition describes the increased use of PET scanning in staging and follow-up. Chapters discuss current treatment optionsincluding combination chemotherapy, radiation therapy, novel treatment techniques, and hematopoietic stem cell transplantationand offer guidelines for treatment selection. Full consideration is given to late effects of therapy and clinical trials for assessing quality of life in patients. This edition includes complete access... |
| © 2009 BrightSurf.com |